Cellectar Biosciences, Inc. (CLRB) stock
CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.92−0.09 (-8.88%)
Close on Nov 17, 2026Market cap $8.70MP/E –Yield –
Cellectar Biosciences operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Cellectar Biosciences's operating income for the twelve months ending Jun 30, 2026 was -$23.53M. For fiscal 2025 it was -$22.98M. The highest annual figure on record is -$4.19M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$22.98M | – |
| FY2024 | Dec 31, 2024 | -$51.78M | – |
| FY2023 | Dec 31, 2023 | -$38.96M | – |
| FY2022 | Dec 31, 2022 | -$28.81M | – |
| FY2021 | Dec 31, 2021 | -$24.13M | – |
| FY2020 | Dec 31, 2020 | -$15.29M | – |
| FY2019 | Dec 31, 2019 | -$14.18M | – |
| FY2018 | Dec 31, 2018 | -$13.33M | – |
| FY2017 | Dec 31, 2017 | -$13.60M | – |
| FY2016 | Dec 31, 2016 | -$9.45M | – |
| FY2015 | Dec 31, 2015 | -$8.76M | – |
| FY2014 | Dec 31, 2014 | -$9.89M | – |
| FY2013 | Dec 31, 2013 | -$12.40M | – |
| FY2012 | Dec 31, 2012 | -$8.75M | – |
| FY2011 | Dec 31, 2011 | -$7.04M | – |
| FY2010 | Dec 31, 2010 | -$4.19M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$7.20M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.79M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.85M | – |
| Q2 FY2025 | Jun 30, 2025 | -$6.04M | – |
| Q1 FY2025 | Mar 31, 2025 | -$6.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.74M | – |
| Q3 FY2024 | Sep 30, 2024 | -$13.33M | – |
| Q2 FY2024 | Jun 30, 2024 | -$13.70M | – |
| Q1 FY2024 | Mar 31, 2024 | -$12.00M | – |
| Q4 FY2023 | Dec 31, 2023 | -$12.55M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.41M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.29M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.71M | – |
| Q4 FY2022 | Dec 31, 2022 | -$7.42M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.82M | – |
| Q2 FY2022 | Jun 30, 2022 | -$7.44M | – |
| Q1 FY2022 | Mar 31, 2022 | -$6.14M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.82M | – |
| Q2 FY2021 | Jun 30, 2021 | -$6.03M | – |
| Q1 FY2021 | Mar 31, 2021 | -$6.36M | – |
| Q4 FY2020 | Dec 31, 2020 | -$3.80M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.91M | – |
| Q2 FY2020 | Jun 30, 2020 | -$3.62M | – |
| Q1 FY2020 | Mar 31, 2020 | -$3.96M | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.38M | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.96M | – |
| Q2 FY2019 | Jun 30, 2019 | -$3.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$3.63M | – |
| Q4 FY2018 | Dec 31, 2018 | -$3.88M | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.09M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.90M | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.45M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.09M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.48M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.22M | – |
| Q1 FY2017 | Mar 31, 2017 | -$2.81M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.65M | – |
| Q3 FY2016 | Sep 30, 2016 | -$2.47M | – |
See a number that looks wrong?